Your browser doesn't support javascript.
loading
Blastic Epstein-Barr virus associated post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation for severe aplastic anemia.
Hotta, Masaaki; Nakaya, Aya; Fujita, Shinya; Satake, Atsushi; Nakanishi, Takahisa; Azuma, Yoshiko; Tsubokura, Yukie; Konishi, Akiko; Yoshimura, Hideaki; Ito, Tomoki; Ishii, Kazuyoshi; Nomura, Shosaku.
Afiliación
  • Hotta M; First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
  • Nakaya A; First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
  • Fujita S; First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
  • Satake A; First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
  • Nakanishi T; First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
  • Azuma Y; First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
  • Tsubokura Y; First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
  • Konishi A; First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
  • Yoshimura H; First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
  • Ito T; First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
  • Ishii K; First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
  • Nomura S; First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Hematol Rep ; 10(2): 7527, 2018 May 14.
Article en En | MEDLINE | ID: mdl-30046412
Post-transplant lymphoproliferative disorder (PTLD) is a well-recognized complication of organ transplantation. Progress has recently been made in the pathological classification of PTLD. However, the clinical course has not been clarified because of the rarity of this disease. We experienced a case of PTLD with a fulminant clinical course. The patient had been under longterm immunosuppressive treatment for aplastic anemia. He received related allogeneic hematopoietic stem cell transplantation. Soon after transplantation, he developed PTLD. According to the guidelines, we reduced immunosuppression. However, the disease course was so fulminant that there was no time for the patient to respond, and he died of multi-organ failure. There may be various clinical types of PTLD, which may include some fulminant cases. In such a case, it is not sufficient to reduce immunosuppression. The patient should be carefully observed and an appropriate individual treatment should be chosen.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Risk_factors_studies Idioma: En Revista: Hematol Rep Año: 2018 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Risk_factors_studies Idioma: En Revista: Hematol Rep Año: 2018 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza